Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Barclays PLC (BCS) vs TransMedics Group Inc (TMDX) Price & Performance

Barclays PLCTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Barclays PLC vs TransMedics Group Inc — how do they compare? Barclays PLC trades at $28.04 (market cap $93.87B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Barclays PLC is far larger — about 30.3× TransMedics Group Inc's market cap, and Barclays PLC pays a 2.19% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

BCSTMDX
Market Cap
$93.87B$3.10B
Sector
FinancialsTechnology
52-Week High
$28.56$150.42
52-Week Low
$19.36$61.99
Dividend Yield
2.19%
Enterprise Value
$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Barclays PLC

Barclays PLC (BCS) trades at $28.09, up 0.39% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows a low P/E of 10.68 and P/B of 0.88, indicating potential undervaluation. Revenue grew to $29.14B in 2025, with net income margin at 25.51%, though cash flow volatility from 2023-2024 remains a concern. Recent news highlights a securities investigation and mixed analyst views post-Q2 results.

Outlook is cautiously optimistic due to valuation appeal and earnings strength, but risks include legal scrutiny and cost pressures. Analyst consensus is 68% buy, with sentiment tempered by near-term headwinds. The stock offers value if operational efficiency improves, yet investors should monitor the class-action probe and expense trends.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Barclays PLC

Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments

Read more on BCS

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX